28 Result(s)

Article

The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults

The introduction of the tyrosine kinase inhibitors (TKI) into the treatment of patients with Ph or BCR-ABL1-positive acute lymphoblastic leukemia has revolutionized the treatment of this poor prognosis acute leuk...

M R Litzow, A K Fielding, S M Luger, E Paietta, Y Ofran… in Bone Marrow Transplantation (2017)

Article

Very late relapse of AML after allogeneic hematopoietic cell transplantation is often extramedullary

J M Watts, X V Wang, R T Swords, E Paietta, D Douer… in Bone Marrow Transplantation (2016)

Article

Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition

PTPN11 encodes the Shp2 non-receptor protein-tyrosine phosphatase implicated in several signaling pathways. Activating mutations in Shp2 are commonly associated with juvenile myelomonocytic leukemia but are not a...

L Chen, W Chen, M Mysliwski, J Serio, J Ropa, F A Abulwerdi, R J Chan… in Leukemia (2015)

Article

PHF6 mutations in adult acute myeloid leukemia

Loss of function mutations and deletions encompassing the plant homeodomain finger 6 (PHF6) gene are present in about 20% of T-cell acute lymphoblastic leukemias (ALLs). Here, we report the identification of recu...

P Van Vlierberghe, J Patel, O Abdel-Wahab, C Lobry, C V Hedvat, M Balbin… in Leukemia (2011)

Article

Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia

R Bhat, S Malinge, A S Gamis, A D Sorrell, J M Hilden, R P Ketterling… in Leukemia (2009)

Article

Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998)

The Eastern Cooperative Oncology Group (ECOG) performed a phase 2 study in B-cell chronic lymphocytic leukemia (CLL) of oral theophylline, a methylxanthine that inhibits cyclic nucleotide phosphodiesterases, t...

P H Wiernik, E Paietta, O Goloubeva, S J Lee, D Makower, J M Bennett, J L Wade… in Leukemia (2004)

Article

Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide

AP-1060 is a newly established acute promyelocytic leukemia (APL) cell line from a multiple-relapse patient clinically resistant to both all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). The line was ini...

Y Sun, S H Kim, D-C Zhou, W Ding, E Paietta, F Guidez, A Zelent, K H Ramesh… in Leukemia (2004)

Article

Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials

CD65s appears when the progenitor antigen CD34 disappears, suggesting that this sialylated carbohydrate antigen marks a turning point in normal myeloid differentiation. We characterized acute myeloid leukemia ...

E Paietta, D Neuberg, J M Bennett, G Dewald, J M Rowe, P A Cassileth, L Cripe… in Leukemia (2003)

Article

Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept?

The term minimal residual disease (MRD) in its currently accepted application refers to low-level disease detected in a whole variety of clinical situations. It is used to describe residual disease after subop...

E Paietta in Bone Marrow Transplantation (2002)

Chapter

Treatment of Poor Prognosis AML Patients Using PSC833 (Valspodar) Plus Mitoxantrone, Etoposide, and Cytarabine (PSC-MEC)

The failure of convenional chemotherapy in relapsed or refractory and other poor risk AML patients has been linked to expression of the multidrug resistance gene (mdr1) product P-glycoprotein (P-gp). PSC 833 is a...

R. Advani, G. Visani, D. Milligan, H. Saba… in Drug Resistance in Leukemia and Lymphoma I… (1999)

Article

Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience

Evaluable karyotypes were available in 776 of 1148 adult patients who were entered on acute myeloid leukemia (AML) treatment protocols of the Eastern Cooperative Oncology Group. Among these, we found seven pat...

E Paietta, J Racevskis, JM Bennett, D Neuberg, PA Cassileth, JM Rowe… in Leukemia (1998)

Article

Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992

This study was a phase II evaluation of the activity of carboplatin in patients with Philadelphia chromosome positive accelerated or blastic phase of CML. Carboplatin, 250 mg/m²/day as an intravenous continuous i...

JP Dutcher, S Lee, E Paietta, JM Bennett, JA Stewart, PH Wiernik in Leukemia (1998)

Chapter and Conference Paper

Treatment of Poor Prognosis Acute Myelogenous Leukemia with PSC-833 and Mitoxantrone, Etoposide, Cytarabine

A major reason for failure of conventional treatment in acute myeloid leukemia (AML) is primary or secondary resistance of the leukemic cells to anti-neoplastic drugs. One of these mechanisms is characterized ...

R. Advani, H. Saba, M. Tallman, J. M. Rowe, P. Wiernik, J. Ramek… in Acute Leukemias VII (1998)

Article

Expression of CD25 (interleukin-2 receptor α chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993

Of 144 adult Eastern Cooperative Oncology Group (ECOG) patients with acute lymphoblastic leukemia (ALL) entered on study E2993 at the time of analysis, 104 had informative immunophenotypes and molecular analys...

E Paietta, J Racevskis, D Neuberg, JM Rowe, AH Goldstone, PH Wiernik in Leukemia (1997)

Chapter and Conference Paper

Cytomorphology and Clinical Outcome in 80 Patients with AML M4Eo and Inversion 16

We analyzed specific cytomorphological aspects and treatment results in 80 patients with AML M4Eo and inversion 16. All patients were treated according to protocols of the AMLCG (n=60) or the ECOG (n=20). Several...

T. Haferlach, H. Löffler, J. M. Bennett, J. W. Andersen, W. Gassmann… in Acute Leukemias VI (1997)

Chapter and Conference Paper

Incidence of Infections in Adult Patients (> 55 Years) with Acute Myeloid Leukemia Treated with Yeast-Derived GM-CSF (Sargramostim): Results of a Double-Blind Prospective Study by the Eastern Cooperative Oncology Group

Between 9/90 and 11/92, the ECOG conducted a double-blind randomized trial of yeast-derived GM-CSF (Sargramostim) versus placebo in 124 patients age > 55–70 with de novo acute myeloid leukemia (AML). Induction th...

J. M. Rowe, A. Rubin, J. J. Mazza, J. M. Bennett, E. Paietta… in Acute Leukemias V (1996)

Chapter and Conference Paper

Evaluation of In Vivo Natural Killer and Lymphokine-Activated Killer Cell Activity in Patients Treated with High-Dose Interleukin-2 and Adoptive Transfer of Autologous LAK Cells

A substantial number of Phase I and Phase II clinical trials of interleukin-2 (IL-2) alone or combined with adoptive transfer of lymphokine-activated killer (LAK) cells in the treatment of cancer patients had ...

J. Walewski, E. Paietta, J. Dutcher… in Cytokines in Hemopoiesis, Oncology, and AI… (1990)

Article

Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells

This study investigated the development of peripheral blood natural killer (NK) and lymphokineactivated killer (LAK) cell activity in vivo in cancer patients treated with high doses of recombinant interleukin-...

J. Walewski, E. Paietta, J. Dutcher… in Journal of Cancer Research and Clinical On… (1989)

Chapter and Conference Paper

A Marker and Putative Pathoantigen of Hodgkin’s Cells

Hodgkin’s disease has become a curable disease thanks to the sensitivitiy of its abnormal cells to available treatment strategies. However, the origin of these malignant cells, the typical giant, multinucleate...

E. Paietta, R. J. Stockert, A. Morell… in New Aspects in the Diagnosis and Treatment… (1989)